|
|
Upfront Briefing
Tyra put up a 64% complete response rate in bladder cancer when the Street had circled 70%, and the stock lost nearly a fifth of its value over the rounding error. Bayer had a tidier day, taking Hyrnuo into first-line HER2-mutant lung cancer about six months after Boehringer got there. Private money kept flowing: Encoded closed $275M to take its Dravet gene therapy pivotal, and Solstice launched on a $225M Series A. WCLC opens in Seoul on Saturday, so enjoy the quiet before the lung-cancer data lands.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,636.4 |
(0.5%) |
+11.3% |
| Nasdaq 100 |
29,421.6 |
(0.3%) |
+16.7% |
| Russell 2000 |
2,921.2 |
(1.3%) |
+16.5% |
| Healthcare (XLV) |
166.6 |
(0.3%) |
+7.1% |
| Biotech (XBI) |
159.4 |
(1.6%) |
+31.2% |
| Nasdaq Biotech (NBI) |
7,016.9 |
(0.9%) |
+23.0% |
| Clinical Trials (BBC) |
51.5 |
(3.1%) |
+36.9% |
|
- Biotech lagged a soft tape: XBI fell 1.6% and NBI 0.9% while XLV gave up just 0.3%, leaving the equal-weight group trading with the Russell 2000 rather than large-cap healthcare. Clinical-stage names took the worst of it, with BBC down 3.1% on a session where Tyra (nearly 20% lower on Phase 2 bladder data) and Evommune (a second Phase 2b miss) had both reported before the open.
- Stocks fell for a third straight session as October crude rose 3.9% to $96.69 on Iranian escalation warnings and the 10-year yield climbed to roughly 4.85% after Treasury tripled its long-dated buyback to $6B; the Russell 2000 dropped 1.3% and the S&P 500 0.5%.
- Market data: U.S. cash close Wednesday, 9 September 2026.
The Big 3
|
1
|
Tyra's bladder cancer pill hits 64% CR against a 70% bar
|
- Tyra reported initial Phase 2 SURF302 data for oral, FGFR3-selective dabogratinib in FGFR3-altered low-grade intermediate-risk NMIBC: 79% ORR and 64% best complete response at 60 mg once daily (31 Aug cut), with no grade 3 or worse treatment-related events at that dose across a 44-patient safety set. Shares fell nearly 20%; Tyra still plans a registrational adjuvant study next year and is adding a 70 mg cohort.
- Why it matters: Piper Sandler and H.C. Wainwright had both framed a 70% three-month complete response rate as the bar, so 64% trades as a miss despite clean safety. The cut that matters for the adjuvant plan looks better: single-marker-lesion patients at 60 mg posted 100% ORR and 75% CR, but that is eight patients. Tyra is selling convenience, a once-daily pill in a setting where about 70% of eligible patients skip intravesical therapy, and it has to take share from UroGen's approved Zusduri and J&J's TAR-210. The 70 mg cohort now tests whether more drug lifts CR without the FGFR1/2 toxicity that limits Balversa. Piper had modelled the indication above $1B; the probability attached to that number just fell.
- Source: Endpoints
- More: Fierce Biotech; BioPharma Dive
|
|
2
|
FDA clears Bayer's Hyrnuo in first-line HER2-mutant lung cancer
|
- FDA expanded the accelerated approval of Hyrnuo (sevabertinib) to first-line HER2 (ERBB2) TKD-mutant non-squamous NSCLC, removing the prior-therapy requirement from its November 2025 label. The decision rests on 69 patients in the single-arm Phase 1/2 SOHO-01 trial, with a 75% objective response rate (95% CI 64–85%).
- Why it matters: Bayer is running this race from second place. Boehringer's Hernexeos took the same first-line setting about six months ago on a similar single-arm package, so there is no label lead to sell and no head-to-head data to separate the two. Share will turn on tolerability, once-daily Hernexeos against twice-daily Hyrnuo, and on how fast HER2 TKD testing becomes routine at diagnosis for a mutation found in only a few percent of NSCLC. Moving up a line widens the treatable pool for a launch that only began in November, useful for a pharma group still working through the Xarelto patent cliff, if small against Bayer's scale. Accelerated status leaves the randomised SOHO-02 Phase 3 as the swing factor, and a miss there would put the first-line label back in play.
-
Source:
Fierce Pharma
-
More:
Healio
|
| 3 | Encoded closes $275M Series F to take Dravet gene therapy pivotal |
- Encoded closed a $275M Series F co-led by GV and an undisclosed healthcare fund, with ARCH Venture Partners, Braidwell, Farallon, Illumina Ventures, Invus, Janus Henderson, Matrix, Nolan Capital, RTW, SoftBank Vision Fund 2 and Venrock participating. Proceeds fund the pivotal study of ETX101 in infants and young children with SCN1A+ Dravet syndrome, an expansion study up to age 18, and commercial scale-up of its internal GMP facility.
- Why it matters: $275M is late-stage money for a private gene therapy company, and a crossover-heavy syndicate (Janus Henderson, RTW, Farallon, Braidwell) is usually assembled with an IPO in mind once pivotal data come into view. Building commercial-scale GMP capacity in-house cuts reliance on CDMOs, a recurring bottleneck for AAV programmes. Public investors will run the comparison against Stoke Therapeutics' zorevunersen, an antisense drug aimed at the same SCN1A haploinsufficiency, in Phase 3 and partnered with Biogen outside North America, which needs repeat intrathecal dosing; ETX101 is a one-time AAV9 treatment. The risks belong to the modality: dosing infants with AAV, durability of expression, and a developmental-endpoint bar no Dravet programme has yet cleared at FDA. Interim POLARIS data showed seizure reductions; the pivotal study has to confirm them.
-
Source:
Endpoints
-
More:
Fierce Biotech
|
Everything Else that broke
- Evommune's oral MRGPRX2 antagonist EVO756 missed its primary endpoint in a Phase 2b atopic dermatitis trial, its second Phase 2b failure since June's chronic urticaria miss; the drug now continues only in migraine, with EVO301 taking over in eczema. — Endpoints
- Beeline Medicines' oral TLR7/8 inhibitor afimetoran, acquired from Bristol Myers Squibb, beat placebo on SRI-4 response at week 48 at all three doses (p<0.001) in a Phase 2 lupus trial; effect sizes are being held for a medical meeting, and pivotal work is planned in systemic and cutaneous lupus. — Endpoints
- Compass Pathways posted 52-week open-label COMP005 data for COMP360 psilocybin in treatment-resistant depression, showing a 13-point drop in depression score, with its NDA under rolling review on a national priority voucher. — Endpoints
- Nanoscope said the FDA accepted and filed its BLA for MOGENRY in retinitis pigmentosa with severe vision loss, adding another genetic-medicine decision to the calendar. — PR
- Insilico dosed the first patient in Phase 3 GENESIS-IPF-3 for rentosertib in idiopathic pulmonary fibrosis. — PR
- Seismic started a global Phase 3 trial of istaroxime in cardiogenic shock, targeting about 600 patients. — PR
- Luma Group closed its inaugural life sciences venture fund at $410M, with a 15-year fund life. — Fierce Biotech
- Merck cut another 54 jobs at its Rahway, New Jersey headquarters, effective December and January, under its multiyear cost-cutting programme. — Fierce Pharma
- The orexin research behind narcolepsy, and behind Takeda's newly approved Orzeyful, won a Lasker Award. — Endpoints
- ARPA-H picked UpDoc, Tempus AI and Atman Health to build agentic AI tools for heart disease. — Endpoints
- ARPA-H backed four rare-disease AI diagnostics projects for earlier detection tools. — BioCentury
- Researchers urged the FDA to broaden drug rejection disclosures to better mirror the EMA. — Endpoints
- The PDUFA VIII debate is tilting toward review speed over a proposed 50% fee discount. — BioSpace
- UK pharma investment picked up after last year's lull as improved government medicine payments helped sentiment. — Pharmaceutical Executive
- CordenPharma committed €80M to lift aseptic fill-finish capacity to 500M sterile injectable units yearly. — PR
- DecisionDx-SCC data showed 97.3% negative predictive value for Class 1A low-risk results. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Kura Oncology spun out Caspian Therapeutics with $50M in funding and Lilly's backing to develop menin inhibitors in diabetes and cardiometabolic disease. — BioPharma Dive
- Ratio Therapeutics signed a research collaboration and licence with RayzeBio, Bristol Myers Squibb's radiopharmaceutical unit, on a programme against two undisclosed targets, for upfront cash plus development, regulatory and commercial milestones and royalties. — PR
- Labcorp acquired MLM Medical Labs to expand its laboratory services footprint. — Fierce Biotech
VC / Private Financings
- Encoded Therapeutics raised a $275M Series F for Dravet gene therapy ETX101, co-led by GV and an undisclosed healthcare fund, joined by ARCH Venture Partners, RTW, SoftBank Vision Fund 2 and Venrock. — Endpoints
- Solstice Oncology launched with a $225M Series A to take Harbour BioMed-licensed CTLA-4 antibody porustobart into a neoadjuvant Phase 2 in MSS colon cancer, led by RA Capital Management, joined by Canaan Partners and Forbion. — Fierce Biotech
- TwoStep raised $62.5M to take its ADC approach into the clinic. — Endpoints
- Schrödinger launched immunology spinout Tectora Therapeutics on a $55M Series A. — Fierce Biotech
IPOs / Follow-Ons
- No notable IPOs or follow-ons in the last 24 hours.
Academic Corner - Oveporexton improved wakefulness, daytime sleepiness and cataplexy in two Phase 3 narcolepsy type 1 trials. — NEJM
- A NEJM commentary called obinutuzumab a step forward in membranous nephropathy. — NEJM
|
Somewhere, an analyst is quietly redrawing a 70% line at 64%.
— BioBucks Team
|
|
|
